

Cemiplimab
Essential medicine status
General description

INN
Cemiplimab
ATC codes
[L01FF06](#)
Medicine type
Biological agent
EML status history
First added in 2025 ([TRS 1064](#)) for [Other specified malignant neoplasms of bronchus or lung](#)
Application rejected in 2025 ([TRS 1064](#)) for [Adenocarcinoma of stomach](#)
Added in 2025 ([TRS 1064](#)) for [Other specified malignant neoplasms of bronchus or lung](#)
Therapeutic equivalent for
[pembrolizumab](#) for [Other specified malignant neoplasms of bronchus or lung](#)
[pembrolizumab](#) for [Adenocarcinoma of stomach](#)
Wikipedia
[Cemiplimab](#)
DrugBank
[Cemiplimab](#)
Recommendations
Section
Immunomodulators

- Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion

Indications
[Other specified malignant neoplasms of bronchus or lung](#)